Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
NUFYMCO BLA has been approved by the USFDA
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Subscribe To Our Newsletter & Stay Updated
